论文部分内容阅读
目的评价滋水涵木中药联合西药美多巴片治疗帕金森病的临床疗效。方法将28例帕金森病患者随机分为治疗组18例和对照组10例,两组均给予美多巴片,第1周口服每次125mg,每日2次,其后每隔1周每日增加125mg,直至每日量750mg,分3次服;治疗组另加服滋水涵木中药,每日1剂,连续6个月。治疗后观察临床疗效,记录治疗前、治疗后3个月及6个月帕金森病综合评分量表(UPDRS)评分,并观察不良反应。结果两组临床疗效比较,治疗组总有效率(72.22%)明显高于对照组(60.00%)(P<0.05)。两组治疗后3个月、6个月与治疗前比较,UPDRS评分均有显著下降(P<0.05);与治疗3个月比较,两组治疗后6个月UPDRS评分明显降低(P<0.05)。治疗后6个月,UPDRS评分两组间比较差异有统计学意义(P<0.05)。治疗组不良反应率为11.11%,对照组为50.00%,两组比较差异有统计学意义(P<0.05)。结论滋水涵木中药联合美多巴片治疗帕金森病疗效优于单纯使用西药,且不良反应较少。
Objective To evaluate the clinical efficacy of Zishui Hanmu combined with western medicine methopromycin in the treatment of Parkinson’s disease. Methods 28 patients with Parkinson’s disease were randomly divided into treatment group (n = 18) and control group (n = 10) .Metabol tablets were given in both groups. The first two weeks were orally administered with 125mg twice daily and every other week thereafter Daily increase of 125mg, until the daily amount of 750mg, 3 times service; treatment group plus service Han Chinese herbal medicine, daily 1, for 6 months. After treatment, the clinical efficacy was observed. Pre-treatment, post-treatment, 3-month and 6-month UPDRS scores were recorded and adverse reactions were observed. Results The clinical efficacy of the two groups was significantly higher than that of the control group (72.22% vs 60.00%, P <0.05). The UPDRS scores were significantly decreased in both groups at 3 months and 6 months after treatment (P <0.05). Compared with the 3-month treatment, the UPDRS scores of the two groups were significantly lower at 6 months after treatment (P <0.05 ). Six months after treatment, UPDRS score was significantly different between the two groups (P <0.05). Adverse reaction rate was 11.11% in the treatment group and 50.00% in the control group, with significant difference between the two groups (P <0.05). Conclusion Zishui Han Chinese medicine combined with Meodoba tablets treatment of Parkinson’s disease is better than the simple use of western medicine, and less adverse reactions.